^
PD-L1 overexpression
Follicular Lymphoma
PD-L1 inhibitor
Sensitive: C4 – Case Studies
Cancer Biol Ther - 3 weeks
PD-L1 overexpression
Follicular Lymphoma
R-GemOx
Resistant: C4 – Case Studies
Cancer Biol Ther - 3 weeks
PD-L1 overexpression
Follicular Lymphoma
R-CHOP
Resistant: C4 – Case Studies
Cancer Biol Ther - 3 weeks
No biomarker
Follicular Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
rituximab + lenalidomide
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
Truxima (rituximab biosimilar)
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
Rixathon (rituximab biosimilar)
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
Ruxience (rituximab biosimilar)
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
obinutuzumab
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
rituximab
Sensitive: A1 - Approval
CD20 positive
Follicular Lymphoma
rituximab + ibritumomab tiuxetan
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
ibritumomab tiuxetan
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
idelalisib
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
duvelisib
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
tazemetostat
Sensitive: A1 - Approval
EZH2 mutation
Follicular Lymphoma
tazemetostat
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
copanlisib
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
umbralisib
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
lisocabtagene maraleucel
Sensitive: A1 - Approval
CD20 positive
Follicular Lymphoma
Ruxience (rituximab biosimilar)
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
rituximab/hyaluronidase
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
R-CHOP
Sensitive: A2 - Guideline
No biomarker
Follicular Lymphoma
R-CVP
Sensitive: A2 - Guideline
No biomarker
Follicular Lymphoma
rituximab + obinutuzumab
Sensitive: A2 - Guideline
No biomarker
Follicular Lymphoma
lenalidomide
Sensitive: A2 - Guideline
No biomarker
Follicular Lymphoma
chlorambucil
Sensitive: A2 - Guideline
No biomarker
Follicular Lymphoma
lenalidomide + obinutuzumab
Sensitive: A2 - Guideline
No biomarker
Follicular Lymphoma
cyclophosphamide oral
Sensitive: A2 - Guideline
No biomarker
Follicular Lymphoma
G-CHOP
Sensitive: A2 - Guideline
No biomarker
Follicular Lymphoma
tisagenlecleucel-T
Sensitive: A2 - Guideline
No biomarker
Follicular Lymphoma
CG-781
Sensitive: B - Late Trials
BCL2 elevation + IGH elevation
Follicular Lymphoma
rituximab
Resistant: B - Late Trials
No biomarker
Follicular Lymphoma
INCB50465
Sensitive: B - Late Trials
CD20 positive
Follicular Lymphoma
Truxima (rituximab biosimilar)
Sensitive: C1 - Off-label
CD20 positive
Follicular Lymphoma
GEN3013
Sensitive: C2 – Inclusion Criteria
BCL2 mutation
Follicular Lymphoma
nivolumab + ibrutinib
Sensitive: C3 – Early Trials
CXCL11 elevation
Follicular Lymphoma
duvelisib
Resistant: C3 – Early Trials
IL2RA elevation
Follicular Lymphoma
duvelisib
Resistant: C3 – Early Trials
Chr del(6q)(q15)
Follicular Lymphoma
duvelisib
Sensitive: C3 – Early Trials
EZH2 mutation
Follicular Lymphoma
rituximab
Resistant: C3 – Early Trials
KMT2D mutation
Follicular Lymphoma
R-CHOP
Resistant: C3 – Early Trials
ARID1B mutation
Follicular Lymphoma
R-CHOP
Resistant: C3 – Early Trials
BCL7A mutation
Follicular Lymphoma
R-CHOP
Resistant: C3 – Early Trials
TNFAIP3 mutation
Follicular Lymphoma
R-CHOP
Resistant: C3 – Early Trials
GNA13 mutation
Follicular Lymphoma
R-CHOP
Sensitive: C3 – Early Trials
CTSS Y132D
Follicular Lymphoma
R-CHOP
Sensitive: C3 – Early Trials
GNA12 mutation
Follicular Lymphoma
R-CHOP
Sensitive: C3 – Early Trials
PLCG2 mutation
Follicular Lymphoma
R-CHOP
Resistant: C3 – Early Trials
IL2-L
Follicular Lymphoma
rituximab
Sensitive: C3 – Early Trials
FCGR2A mutation
Follicular Lymphoma
rituximab + lenalidomide
Sensitive: C3 – Early Trials
TBX21 overexpression
Follicular Lymphoma
nivolumab + ibrutinib
Sensitive: C3 – Early Trials
LDH elevation
Follicular Lymphoma
ViPOR
Sensitive: C3 – Early Trials
MYC rearrangement + BCL6 rearrangement
Follicular Lymphoma
EPOCH-R
Resistant: C3 – Early Trials
MYC rearrangement
Follicular Lymphoma
EPOCH-R
Sensitive: C3 – Early Trials
MYC rearrangement + BCL2 rearrangement
Follicular Lymphoma
EPOCH-R
Sensitive: C3 – Early Trials
MYC rearrangement + BCL2 rearrangement
Follicular Lymphoma
R-DHAP
Sensitive: C3 – Early Trials
IL2RA-L
Follicular Lymphoma
nivolumab
Sensitive: C3 – Early Trials
CD20 positive
Follicular Lymphoma
MB-106
Sensitive: C3 – Early Trials
HAVCR2 expression
Follicular Lymphoma
venetoclax + atezolizumab + obinutuzumab
Sensitive: C3 – Early Trials
CCL19 overexpression
Follicular Lymphoma
rituximab
Sensitive: C3 – Early Trials
RGL1 overexpression
Follicular Lymphoma
rituximab
Sensitive: C3 – Early Trials
CCL19-H
Follicular Lymphoma
rituximab
Sensitive: C3 – Early Trials
BCL2 F104I
Follicular Lymphoma
venetoclax
Resistant: C4 – Case Studies
CREBBP mutation
Follicular Lymphoma
YF2
Sensitive: D – Preclinical
TP53 mutation
Follicular Lymphoma
YF2
Sensitive: D – Preclinical
EZH2 mutation
Follicular Lymphoma
CPI-169
Sensitive: D – Preclinical
TBX21 expression
Follicular Lymphoma
nivolumab + ibrutinib
Sensitive: D – Preclinical